SCHEMBL621869

SCHEMBL621869

CC(C)(CO)NC(=O)c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.71
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
ATM Q13315 1/20 0.59
CYP2C9 P11712 2/20 0.50
CNR1 P21554 1/20 0.50
CNR2 P34972 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
EPHX1 P07099 1/20 0.50
GAA P10253 1/20 0.48
PRSS1 P07477 1/20 0.47
CTSG P08311 1/20 0.47
CTRB1 P17538 1/20 0.47
CMA1 P23946 1/20 0.47
HDAC3 O15379 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
IDO1 P14902 1/20 0.47
ALOX15 P16050 1/20 0.47
HDAC1 Q13547 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2759010 0.87 NPC1 (0.61) POLBNPC1RAB9AATMCNR1
SCHEMBL26661392 0.85 POLB (0.67) POLBNPC1RAB9AATMCYP2C9
SCHEMBL4516395 0.85 POLB (0.71) POLBNPC1RAB9ACYP2C9SMN1; SMN2
SCHEMBL7575404 0.85 POLB (0.61) POLBNPC1RAB9AATMCYP2C9
SCHEMBL1484964 0.83 EPHX1 (0.71) POLBCYP2C9SMN1; SMN2EPHX1GAA
SCHEMBL24263392 0.83 POLB (1.00) POLBNPC1RAB9ACYP2C9SMN1; SMN2
SCHEMBL9623645 0.83 POLB (0.69) POLBNPC1RAB9AATMCYP2C9
SCHEMBL3025327 0.83 POLB (0.69) POLBNPC1RAB9ACYP2C9SMN1; SMN2
SCHEMBL6023280 0.83 NPC1 (0.54) POLBNPC1RAB9AATMCNR1
SCHEMBL706443 0.83 HDAC1 (0.58) POLBNPC1RAB9AATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103608350-A Triazolopyridine compounds BAYER IP GMBH 2014-02-26 CN claimed
CN-121270417-A Synthesis method of N- (hydroxy-2-methylpropan-2-yl) benzamide compound 马鞍山诺恩特医药科技有限公司 2026-01-06 CN disclosed
CN-121270417-A Synthesis method of N- (hydroxy-2-methylpropan-2-yl) benzamide compound 马鞍山诺恩特医药科技有限公司 2026-01-06 CN disclosed
EP-2603098-B1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER FIRMENICH INCORPORATED (US) 2025-08-06 EP disclosed
CN-116162084-A Pyran derivatives as CYP11A1 inhibitors 奥赖恩公司 2023-05-26 CN disclosed
US-11129397-B2 Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer FIREMENICH INCORPORATED (US) 2021-09-28 US disclosed
CN-107365319-B Modulation of chemosensory receptors and ligands associated therewith 弗门尼舍公司 2020-10-27 CN disclosed
CN-106107406-B Methods of improving the stability of sweetness enhancers and compositions comprising stable sweetness enhancers 弗门尼舍公司 2020-06-09 CN disclosed
CN-110115365-A The adjusting that actinism receptor and relative ligand are carried out 西诺米克斯公司 2019-08-13 CN disclosed
US-20190208802-A1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER FIRMENICH INCORPORATED 2019-07-11 US disclosed
US-6610837-B1 Preparation of an oligonucleotide compound of given formula by reacting with given compounds, followed by oxidation or sulfurization ISIS PHARMACEUTICALS, INC. 2003-08-26 US disclosed
US-6121437-A SYNTHESIS OF OLIGONUCLEOTIDES USING OLIGONUCLEOTIDES OR NUCLEOTIDES WITH PROTECTED INTERNUCLEOSIDIC PHOSPHORUS FUNCTIONALITIES WHICH CAN BE REMOVED UNDER MILD CONDITIONS AND PRODUCE NONTOXIC BY-PRODUCTS ISIS PHARMACEUTICALS, INC. (US) 2000-09-19 US disclosed
US-4900725-A CONTRACEPTIVES ROUSSEL UCLAF (FR) 1990-02-13 US disclosed
EP-0262188-A1 STEROIDS COMPRISING A SPIRANIC CYCLE IN POSITION 17, PREPARATION PROCESS AND UTILIZATION THEREOF. ROUSSEL UCLAF (FR) 1988-04-06 EP disclosed
WO-1987005908-A1 STEROIDS COMPRISING A SPIRANIC CYCLE IN POSITION 17, PREPARATION PROCESS AND UTILIZATION THEREOF ROUSSEL-UCLAF (FR) 1987-10-08 WO disclosed
US-4171452-A FUNGICIDES INTERX RESEARCH CORPORATION (US) 1979-10-16 US disclosed
US-4132805-A Novel soft N-chloroamino alcohol derivatives exhibiting antibacterial activity INTERX RESEARCH CORPORATION (US) 1979-01-02 US disclosed
US-4115588-A Antibacterial novel soft n-chloroamino alcohol derivatives INTERX RESEARCH CORPORATION (US) 1978-09-19 US disclosed
US-4092420-A Novel soft N-chloroamino alcohol derivatives exhibiting antibacterial activity INTERX RESEARCH CORPORATION (US) 1978-05-30 US disclosed
US-4036843-A ANTIBACTERIAL INTERX RESEARCH CORPORATION (US) 1977-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11129397-B2 Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer TFEB, TREH, SLC2A8 POLB 2203/4885NPC1 1999/4885RAB9A 2396/4885
US-20190208802-A1 METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER TFEB, TREH, SLC2A8 POLB 2203/4885NPC1 1999/4885RAB9A 2396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.